Anterix reported last night and the market's verdict was immediate: a 26% single-day surge to $81.44, leaving the bears — and the analyst who downgraded the stock just eight days ago — firmly wrong-footed.
The post-earnings move has reshuffled the positioning picture materially. Short interest, which entered the print at 8.6% of the free float (~1.6 million shares), has been trimming steadily since June 8, falling roughly 7% over the week. That unwind accelerated into the print, and the stock's 46% gain over the past month now puts significant pressure on any remaining short holders. Borrow availability remains comfortable at roughly 393% of short interest, and borrowing costs have actually eased to 0.45% — so there is no mechanical squeeze forcing exits, but the economics of holding a short that just moved 26% against you are punishing enough on their own. The options market saw this coming more clearly than the analyst community: the put/call ratio was running at 0.16 on the day of the print, well below its 20-day average of 0.14, with call buying dominating throughout the run-up.
The analyst backdrop looks awkward in hindsight. B. Riley Securities downgraded Anterix to Neutral on June 4 while lifting its target from $44 to $69 — a move that acknowledged the stock's momentum but pulled back on conviction. The stock is now trading at $81.44, more than $12 above that revised target, and the Street's mean target of $63.67 is deeply below the current price. With just one buy and one hold in the formal coverage, the analyst community is thin and already behind the tape. JP Morgan's last move on the name — a target cut to $50 in October 2025 — is too stale to be actionable, but it underscores how comprehensively the Street has been caught out by this move.
The ownership structure adds another layer of interest. Owl Creek Asset Management holds nearly 29% of shares, a concentration that means the stock trades on conviction bets rather than broad institutional flow. Insider activity has been a net seller in recent months — the CFO, CLO, and Chief Legal Officer all trimmed positions in May at prices between $57 and $60 — though those sales were small in scale and came before the post-earnings gap. The CEO had been a buyer in late 2025 at prices near $20–21, a position that now looks prescient.
Today's print is now a data point rather than an anticipation — what it tests next is whether the Street lifts targets and coverage to catch up with a stock that has left its formal consensus behind by more than 25%.
See the live data behind this article on ORTEX.
Open ATEX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
